Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage biotechnology company, announces its participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series. The company, known for its INTASYL® siRNA gene silencing technology aimed at enhancing immune cells' cancer-fighting capabilities, will have CEO and Board Chairman Robert Bitterman present on Thursday, November 7 at 12:00 pm EST.
Stakeholders and investors are invited to attend this live virtual event, with a replay available on Renmark Financial Communications' website. The presentation focuses on Phio's innovative approach to creating new pathways towards a cancer-free future through their proprietary technology.
Phio Pharmaceuticals (NASDAQ: PHIO), una società biotecnologica in fase clinica, annuncia la sua partecipazione alla Serie di Roadshow Virtuali Non-Deal di Renmark Financial Communications. L'azienda, conosciuta per la sua tecnologia di silenziamento genico INTASYL® siRNA, mirata a migliorare le capacità di combattimento contro il cancro delle cellule immunitarie, avrà il CEO e Presidente del Consiglio Robert Bitterman presente il giovedì 7 novembre alle 12:00 EST.
I sostenitori e gli investitori sono invitati a partecipare a questo evento virtuale dal vivo, con una registrazione disponibile sul sito web di Renmark Financial Communications. La presentazione si concentra sull'approccio innovativo di Phio per creare nuove vie verso un futuro senza cancro attraverso la loro tecnologia proprietaria.
Phio Pharmaceuticals (NASDAQ: PHIO), una compañía de biotecnología en etapa clínica, anuncia su participación en la Serie de Roadshow Virtuales No-Trato de Renmark Financial Communications. La empresa, conocida por su tecnología de silenciamiento génico INTASYL® siRNA, que tiene como objetivo mejorar las capacidades de las células inmunitarias para combatir el cáncer, tendrá al CEO y Presidente de la Junta, Robert Bitterman, presentando el jueves 7 de noviembre a las 12:00 pm EST.
Los interesados e inversores están invitados a asistir a este evento virtual en vivo, con una repetición disponible en el sitio web de Renmark Financial Communications. La presentación se centra en el enfoque innovador de Phio para crear nuevos caminos hacia un futuro libre de cáncer mediante su tecnología propietaria.
Phio Pharmaceuticals (NASDAQ: PHIO), 임상 단계의 생명공학 회사,는 Renmark Financial Communications 가상의 비거래 로드쇼 시리즈에 참여할 것이라고 발표했습니다. 암 퇴치 능력을 향상시키기 위해 면역 세포를 겨냥한 INTASYL® siRNA 유전자 침묵 기술로 잘 알려진 이 회사는 11월 7일 목요일 오후 12:00 EST에 CEO이자 이사회 의장인 로버트 비터먼이 발표할 예정입니다.
이해관계자와 투자자는 이 라이브 가상 이벤트에 참석하도록 초대되며, Renmark Financial Communications 웹사이트에서 다시 보기 가능합니다. 이 발표는 Phio의 독창적인 기술을 통해 암 없는 미래를 위한 새로운 경로를 만드는 혁신적인 접근 방식을 중심으로 진행됩니다.
Phio Pharmaceuticals (NASDAQ: PHIO), une société biopharmaceutique en phase clinique, annonce sa participation à la Série de Roadshow Virtuel Non-Deal de Renmark Financial Communications. L'entreprise, connue pour sa technologie de silence génique INTASYL® siRNA visant à améliorer les capacités de lutte contre le cancer des cellules immunitaires, aura le PDG et président du conseil, Robert Bitterman, présent le jeudi 7 novembre à 12h00 EST.
Les parties prenantes et les investisseurs sont invités à assister à cet événement virtuel en direct, avec une rediffusion disponible sur le site Web de Renmark Financial Communications. La présentation met en avant l'approche innovante de Phio pour créer de nouvelles voies vers un avenir sans cancer grâce à leur technologie propriétaire.
Phio Pharmaceuticals (NASDAQ: PHIO), ein biopharmazeutisches Unternehmen in der klinischen Phase, kündigt seine Teilnahme an der Virtuellen Non-Deal Roadshow-Serie von Renmark Financial Communications an. Das Unternehmen, das für seine INTASYL® siRNA-Gensilencing-Technologie bekannt ist, die darauf abzielt, die Krebsbekämpfungskapazitäten von Immunzellen zu verbessern, wird CEO und Vorstandsvorsitzenden Robert Bitterman am Donnerstag, den 7. November um 12:00 Uhr EST präsentieren.
Stakeholder und Investoren sind eingeladen, an dieser Live-Online-Veranstaltung teilzunehmen, die auch als Aufzeichnung auf der Webseite von Renmark Financial Communications verfügbar ist. Die Präsentation konzentriert sich auf Phios innovativen Ansatz, neue Wege zu einer krebsfreien Zukunft durch ihre proprietäre Technologie zu schaffen.
- None.
- None.
Registration Link for Presentation and live Q&A to take place, Thursday, November 7 at 12:00 pm EST
Marlborough Massachusetts--(Newsfile Corp. - November 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company creating new pathways towards a cancer-free future by using its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells announced today that management will present in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc.
Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present on Thursday, November 7 at 12:00 pm EST. A replay of the event may be accessed on the Renmark Financial Communications Inc. website at https://www.renmarkfinancial.com/vndrs.
Phio Pharmaceuticals welcomes stakeholders, investors, and other individual followers to register and attend this live event.
REGISTER HERE: Renmark Virtual Non-Deal Roadshow: NASDAQ - PHIO | Event Registration | Renmark Financial Communications
If the link does not work, please copy and paste into your browser. To ensure smooth connectivity, please access the link above using the latest version of Google Chrome.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company and a pioneer in the RNAi revolution advancing its proprietary INTASYL siRNA gene silencing technology to create pathways towards a cancer-free future. INTASYL can target and silence virtually any gene with high degree of specificity across a wide range of cell types and tissues. INTASYL is designed to enhance the ability of immune cells to more effectively kill tumor cells. INTASYL is designed to enhance adoptive cell therapy. Notably, INTASYL is the only self-delivering RNAi technology that does not require formulation enhancements or manipulations to reach its target.
Phio's lead clinical program, PH-762, is an INTASYL compound that silences PD-1. PH-762 is a potential non-surgical treatment for skin cancers. The on-going Phase 1b study (NCT# 06014086) received FDA clearance for an Investigational New Drug (IND) to evaluate PH-762 in the treatment of cutaneous SCC, melanoma and Merkel cell carcinoma.
For additional information, visit the Company's website, www.phiopharma.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs
Renmark Financial Communications Inc.
James R. Kautz: jkautz@renmarkfinancial.com
Tel: (416)-644-2020 or (212)-812-7680
www.renmarkfinancial.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/228417
FAQ
When is Phio Pharmaceuticals (PHIO) presenting at the Renmark Virtual Non-Deal Roadshow?
Who will represent PHIO at the November 2024 Renmark Virtual Non-Deal Roadshow?
How can investors access the PHIO presentation at the Renmark Virtual Non-Deal Roadshow?
What is the main technology focus of Phio Pharmaceuticals (PHIO)?
